Exosome Therapy from Hypoxia-treated Mesenchymal Stem Cells Reduces TNF-α and Increases VEGF Levels in Fluconazole-Induced Alopecia Model
Abstract
Background: Alopecia is a condition with partial or complete hair loss, leading to psychological distress. Current treatments, such as minoxidil and finasteride, have limited efficacyand side effects. Recent studies suggest that mesenchymal stem cells (MSCs)-derived exosomes offer regenerative potential by modulating inflammation and enhancing hair follicle regeneration, though optimal dosage remains unclear. Tumor necrosis factor-alpha (TNF-α) inhibits hair follicle growth, while vascular endothelial growth factor (VEGF) promotes hair regrowth. This study evaluates exosome therapy from hypoxia (Hypo-Exo)-treated MSCs in modulating TNF-α and VEGF in a fluconazole-induced alopecia-like model..
Materials and methods: An experimental post-test only control group design was used with 30 male Wistar rats, divided into five groups: Healthy group, 0.9% NaCl-treated group, 5% Minoxidil-treated group, 100 μg/mL Hypo-Exo MSCs-treated group, and 200 μg/mL Hypo-Exo MSCs-treated group. TNF-α and VEGF levels were analyzed using ELISA on day 14 post-treatment.
Results: The highest TNF-α level was found in the 0.9% NaCl-treated group (307.46 ± 20.68 pg/mL) and significantly reduced (p<0.05) in 100 μg/mL Hypo-Exo MSCs-treated group (65.38±15.05 pg/mL) and 200 μg/mL Hypo-Exo MSCs-treated group (37.16±7.14 pg/mL). VEGF levels were the highest in the 200 μg/mL Hypo-Exo MSCs-treated group (189.11±9.75 pg/mL) and 100 μg/mL Hypo-Exo MSCs-treated group (158.50±5.33 pg/mL), compared to the 0.9% NaCl-treated group (69.60±15.39 pg/mL).
Conclusion: Hypo-Exo MSCs significantly reduced TNF-α and increased VEGF levels, supporting their potential as a novel regenerative therapy for alopecia.
Keywords: alopecia, TNF-α, VEGF, exosome, hypoxia, mesenchymal stem cells
Full Text:
PDFReferences
Maloh J, Engel T, Natarelli N, Nong Y, Zufall A, Sivamani RK. Systematic review of psychological interventions for quality of life, mental health, and hair growth in alopecia areata and scarring alopecia. J Clin Med. 2023; 12(3): 964, CrossRef.
Al Aboud AM, Syed HA, Zito PM. Alopecia. Treasure Island: StatPearls Publishing; 2025, article.
Legiawati L, Suseno LS, Sitohang IBS, Pratama AI. Hair disorder in dr. Cipto Mangunkusumo cosmetic dermatology and venereology outpatient clinic of Jakarta, Indonesia: A socio-demographic and clinical evaluation. Dermatol Reports. 2022; 14(3): 9341, CrossRef.
Kuty-Pachecka M. Psychological and psychopathological factors in alopecia areata. Psychiatr Pol. 2015; 49(5): 955-64, CrossRef.
Ghanizadeh A, Ayoobzadehshirazi A. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology. 2014; 6(1): 2-4, CrossRef.
Aşkın Ö, Koyuncu Z, Serdaroğlu S. Association of alopecia with self-esteem in children and adolescents. Int J Adolesc Med Health. 2022; 34(5): 315-8, CrossRef.
Gupta S, Goyal I, Mahendra A. Quality of life assessment in patients with androgenetic alopecia. Int J Trichology. 2019; 11(4): 147-52, CrossRef.
Chiang YZ, Bundy C, Griffiths CEM, Paus R, Harries MJ. The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. Br J Dermatol. 2015; 172(1): 130-7, CrossRef.
Salisbury BH, Leslie SW, Tadi P. 5α-Reductase Inhibitors. Treasure Island: StatPearls Publishing; 2025, article.
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021; 84(6): 1644-51, CrossRef.
Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: An open-label and global photographic assessment. Dermatol Ther. 2020; 10(6): 1345-57, CrossRef.
Ajit A, Nair MD, Venugopal B. Exploring the potential of mesenchymal stem cell-derived exosomes for the treatment of alopecia. Regen Eng Transl Med. 2021; 7(2): 119-28, CrossRef.
Dong J, Wu B, Tian W. Exosomes derived from hypoxia-preconditioned mesenchymal stem cells (hypoMSCs-Exo): Advantages in disease treatment. Cell Tissue Res. 2023; 392(3): 621-9, CrossRef.
Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev. 2006; 2(2): 155-62, CrossRef.
Dewi MR, Pratiwi D, Kandhi PW. High TNF-α levels in active phase chronic suppurative otitis media caused by Gram-positive bacteria. Mol Cell Biomed Sci. 2023; 7(2): 75-80, CrossRef.
Hoffmann R, Eicheler W, Huth A, Wenzel E, Happle R. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res. 1996; 288(3): 153-6, CrossRef.
Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol. 2011; 56(5): 494-6. doi: 10.4103/0019-5154.87124, CrossRef.
Puspasari A, Enis RN, Herlambang H. genetic variant of vascular endothelial growth factor (VEGF)-A rs699947 is associated with preeclampsia. Mol Cell Biomed Sci. 2022; 6(2): 70-6, CrossRef.
Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001; 107(4): 409-17, CrossRef.
Rajendran RL, Gangadaran P, Bak SS, Oh JM, Kalimuthu S, Lee HW, et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. Sci Rep. 2017; 7(1): 15560, CrossRef.
Thompson GR, Krois CR, Affolter VK, Everett AD, Varjonen EK, Sharon VR, et al. Examination of fluconazole-induced alopecia in an animal model and human cohort. Antimicrob Agents Chemother. 2019; 63(2): e01384-18, CrossRef.
Huh CH. Exosome for hair regeneration: From bench to bedside. J Am Acad Dermatol. 2019; 81(4): AB62, CrossRef.
Fan L, Zhang C, Yu Z, Shi Z, Dang X, Wang K. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and osteogenesis in rabbit femoral head osteonecrosis. Bone. 2015; 81: 544-53, CrossRef.
Rajendran RL, Gangadaran P, Bak SS, Oh JM, Kalimuthu S, Lee HW, et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. Sci Rep. 2017; 7(1): 15560, CrossRef.
Li Y, Wang G, Wang Q, Zhang Y, Cui L, Huang X. Exosomes secreted from adipose-derived stem cells are a potential treatment agent for immune-mediated alopecia. J Immunol Res. 2022; 2022: 7471246, CrossRef.
Hoffmann R, Eicheler W, Huth A, Wenzel E, Happle R. Cytokines and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res. 1996; 288(3): 153-6, CrossRef.
Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol. 2011; 56(5): 494-6, CrossRef.
Routsi C, Meletiadis J, Charitidou E, Gkoufa A, Kokkoris S, Karageorgiou S, et al. Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic era. Antibiotics. 2022; 11(6): 771, CrossRef.
Zabaglia LM, Sallas ML, Santos MP Dos, Orcini WA, Peruquetti RL, Constantino DH, et al. Expression of miRNA-146a, miRNA-155, IL-2, and TNF-α in inflammatory response to Helicobacter pylori infection associated with cancer progression. Ann Hum Genet. 2018; 82(3): 135-42, CrossRef.
Sekenova A, Li Y, Issabekova A, Saparov A, Ogay V. TNF-α preconditioning improves the therapeutic efficacy of mesenchymal stem cells in an experimental model of atherosclerosis. Cells. 2023; 12(18): 2262, CrossRef.
Hegde S, Naveen K, Athanikar S, Reshme P. Clinical and dermatoscopic patterns of alopecia areata: A tertiary care centre experience. Int J Trichology. 2013; 5(3): 132, CrossRef.
Ye X, Gaucher JF, Vidal M, Broussy S. A structural overview of vascular endothelial growth factors pharmacological ligands: From macromolecules to designed peptidomimetics. Molecules. 2021; 26(22): 6759, CrossRef.
Gargallo V, Gutierrez C, Vanaclocha F, Guerra-Tapia A. Generalized hypertrichosis due to topical minoxidil. Actas Dermosifiliogr. 2015; 106(7): 599-600, CrossRef.
Garg S, Manchanda S. Platelet-rich plasma-an "Elixir" for treatment of alopecia: personal experience on 117 patients with review of literature. Stem Cell Investig. 2017; 4: 64, CrossRef.
Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006; 43(2): 105-15, CrossRef.
Ren J, Sun J, Li Z, Zhao Y, Tuan H. The Impact of Growth Factors in Platelet-Rich Plasma Combination Therapy for Androgenic Alopecia. Dermatol Ther. 2024; 2024(1): 1-7, CrossRef.
Harries M, Macbeth AE, Holmes S, Chiu WS, Gallardo WR, Nijher M, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022; 186(2): 257-65, CrossRef.
Wang X, Liu Y, He J, Wang J, Chen X, Yang R. Regulation of signaling pathways in hair follicle stem cells. Burns Trauma. 2022; 10: tkac022, CrossRef.
Xia S, Weng T, Jin R, Yang M, Yu M, Zhang W, et al. Curcumin-incorporated 3D bioprinting gelatin methacryloyl hydrogel reduces reactive oxygen species-induced adipose-derived stem cell apoptosis and improves implanting survival in diabetic wounds. Burns Trauma. 2022; 10: tkac001, CrossRef.
Salhab O, Khayat L, Alaaeddine N. Stem cell secretome as a mechanism for restoring hair loss due to stress, particularly alopecia areata: narrative review. J Biomed Sci. 2022; 29(1): 77, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v9i3.642
Copyright (c) 2025 Cell and BioPharmaceutical Institute

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute